Skip to main content

Novartis: CVAY736Y2102 Ph1b VAY736 and Ibrutinib patients with CLL on Ibrutinib therapy

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

February 1, 2020

End Date

February 28, 2021
 

Administered By

Duke Cancer Institute

Awarded By

Novartis Pharmaceuticals Corporation

Start Date

February 1, 2020

End Date

February 28, 2021